1 / 7

Graft Versus Host Disease GvHD Treatment Market size in terms of volume and value 2016-2026

Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body.

fmiresearch
Télécharger la présentation

Graft Versus Host Disease GvHD Treatment Market size in terms of volume and value 2016-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Graft Versus Host Disease GvHD Treatment Market Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2016 Future Market Insights www.futuremarketinsights.com sales@futuremarketinsights.com

  2. Future Market Insights (FMI) is apremier provider of syndicated research reports, custom research reports, andconsulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technologyinputs,valuablegrowthinsights,aerialviewofthecompetitiveframework,andfuturemarkettrends. Weprovideresearchservicesat aglobalas wellas regionallevel;keyregionsincludeGCC, ASEAN,andBRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client. Research Capabilities Sector Coverage  Automotive and Transportation  Electronics, Semiconductor, and ICT  Retail and Consumer Products  Industrial Automation and Equipment  Customized Research  Syndicated Research  Investment Research  Social Media Research  Chemicals & Materials  Food and Beverages  Services and Utilities  Energy, Mining, Oil, and Gas Customized Research Subscription Information Syndicated Research For detailed subscription information please contact Hari. T (Sr. Manager -Global Business Development) Investment Research T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com Social Media Research

  3. Report Description Report Description Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body. It is tough to diagnose who might develop GvHD after a transplant. Mild form of GvHD is observed in few cases. While in certain cases GvHD may be fatal. GvHD do not occur when recipient receives their own cells through autologous transplant. Prior to a transplant, cells from possible donors are screened to realize how strictly they match the recipient. Chances of GvHD are reduced, or symptoms will be milder, when the match is close. Request free sample Report: http://www.futuremarketinsights.com/reports/sample/rep- gb-1401 There are two forms of GvHD: • Acute graft versus host disease (aGvHD). • Chronic graft versus host disease (cGvHD).

  4. Report Description Report Description Graft Versus Host Disease (GvHD) Treatment Market: Drivers and Restraints Presently, graft versus host disease (GvHD) market is driven by increase in number of incidence and prevalence of cancer patients which are treated by chemotherapy treatment. Graft versus host disease (GvHD) global market is also fueled by increase in number of bone marrow transplants been carried around the globe to treat specific types of cancers. Increase in allogeneic hematopoietic stem cell transplant will play key role in global market for graft versus host disease (GvHD). However, cost linked with recent clinical trials and authorizations would acts as a major restraint for graft versus host disease (GvHD) global market. Graft versus Host Disease (GvHD) Treatment: Segmentation Global Graft versus host disease (GvHD) marketis segmented into following product type, and region: Based on product type segment, global Graft versus host disease (GvHD) market is segmented into: • Monoclonal antibodies • mTOR inhibitors • Tyrosine kinase inhibitors

  5. Report Description Report Description • Thalidomide • Etanercept Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1401 Graft versus Host Disease (GvHD) Treatment Market: Overview The global market graft versus host disease (GvHD) treatmentis expected to register a healthy CAGR during the forecast period. Innovative development of novel technologies, and increase in the number of cancer patients seeking for chemotherapy treatment is expected to drive the growth of graft versus host disease (GvHD) treatmentmarket in the forecast period (2016-2026). Graft versus Host Disease (GvHD) Treatment Market: Region-wise Outlook Depending on geographic regions, global medical graft versus host disease (GvHD) treatment marketis segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa. In terms of region Europe holds for the largest market shares in global market graft versus host disease (GvHD) treatmentowing to improvements in medical research, clinical trials, growing geriatric population with cancer indication. Whereas, North America and Asia-Pacific is likely to grow at a substantial growth due to large incidence and prevalence of cancer patientswill contribute to the global graft versus host disease (GvHD) treatmentmarket value showing a healthy CAGR during the forecast period, 2016- 2026.

  6. Report Description Report Description The market for graft versus host disease (GvHD) treatment in various regions is particularly driven by gradually increasing awareness, rising number of chemotherapies and adoption of advanced technologies in cancer treatment. Browse full report: http://www.futuremarketinsights.com/reports/graft-versus-host- disease-gvhd-treatment-market Graft versus Host Disease (GvHD) Treatment Market: Key Players Some of the key participating global players in graft versus host disease (GvHD) treatment global market are Sanofi, Novartis AG, Neovii Biotech GmbH,Merck & Co., Astellas Pharma Inc.,Soligenix, Inc., Mesoblast Ltd and others.

  7. Thank You! To know more about us, please visit our website: www.futuremarketinsights.com For sales queries or new topics email us on: sales@futuremarketinsights.com For other queries contact: Mr. Sudip Saha Future Market Insights: 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 | D: +1-845-579-5705

More Related